7th ICHNO Abstract book

7th ICHNO 7 th ICHNO Conference International Conference on innovative approaches in Head and Neck Oncology 14 – 16 March 2019 Barcelona, Spain __________________________________________________________________________________________ page 75

cancer is challenging. The criteria for initial decision- making needs to be further refined. PO-144 Follow-up of the Head and Neck cancer patients after therapy - are we doing right things? H. Irjala 1 , E. Kytö 1 , E. Haapio 1 , H. Minn 2 1 Turku University Hospital, Department of Otorhinolaryngology and Head and Neck Surgery, Turku, Finland; 2 Turku University Hospital, Department of Oncology, Turku, Finland Purpose or Objective Head and neck cancer follow-up length, interval and content is controversial and therefore we wanted to evaluate the efficacy of the follow-up protocol after curative treatment in head and neck cancer patients. Material and Methods Clinical data of 456 patients with new malignancy of the head and neck in Turku University Hospital district during 1999-2008 were analysed. We evaluated the time, symptoms and the second line treatment outcome of the patients with recurrent disease . Results A total of 94 (22%) patients had relapse during the 5 year follow-up. 90% of recurrences were found within 3 years. 56% of patients had subjective symptoms indicating recurrent tumour. All recurrent tumours found in routine follow-up without symptoms were found within 34 months after the treatment was completed. Conclusion Routine follow-up after 3 years is questionable. Only 2% of the patients were detected a recurrent disease after this time point. All late recurrences in our material had symptoms from disease and an easy access to extra follow- up visit when symptoms occur could well cover the need of this late follow-up. PO-145 Voice outcome in patients with early glottic cancer following radiotherapy versus laser microsurgery A. Allajbej 1 , F. Patani 2 , S. Di Biase 2 , D. Fasciolo 2 , C. Di Carlo 2 , C. Rosa 2 , L. Gasparini 2 , M. Di Francesco 3 , G. Falcone 4 , G. Quaternato 5 , A. Croce 5 , A. Di Pilla 2 , M. Trignani 2 , D. Genovesi 2 1 SS.Annunziata, Radiotherapy, Chieti, Italy; 2 SS Annunziata, Radiotherapy, Chieti, Italy; 3 Papa Paolo VI Fondation, Speech Rehabilitation, Chieti, Italy; 4 Papa Paolo VI Fondation, Phoniatrics, Chieti, Italy; 5 SS Annunziata, Otorhinolaryngology, Chieti, Italy Purpose or Objective Oncological outcome of patients affected by early glottic cancer (EGC) treated with radiotherapy (RT) either Laser microsurgery (LM) is similar, but voice quality (VQ) outcome and voice quality handicap following these treatment modalities are not clear. The aim of our study is to report clinical outcomes focalizing on voice quality of patients who received either RT or LM. Material and Methods We evaluated 45 EGC patients (Tis, T1 and T2 stages) submitted to primary RT or LM between 2008-2017. Overall survival (OS), progression free survival (PFS) and radiation induced toxicities according to CTCAE v. 4.0 scale were evaluated. For a subsample of this ECG population a prospective VQ evaluation is ongoing. Enrollment of patient for VQ evaluation will include at least 20 patients, performing multi-modality voice analyses. Voice evaluation includes: Voice Handicap Index (VHI-30), objective analysis using PRAAT software and perceptual rating performed by speech therapist (GRBAS

for AP in hypopharyngeal and oropharyngeal exclusive radiotherapy; an altered SWt 2 at 50 Gy was predicitive for AP in postoperative oral cavity (p = .03) and laryngeal cancers ( p<.05 ) . Radiation technique was significantly correlated to AP for SWt 2 at 30 Gy (p =0.41). At multivariate the SWt2 at baseline and at 30 Gy were confirmed as indipendent factors. Conclusion This retrospective study confirms the usefullness of swallowing tests at baseline to identified patients at risk of AP. PO-143 Long-term Functional Outcome after Laryngeal Cancer Treatment R. Giger 1 , L. Anschuetz 1 , M. Shelan 2 , M. Dematté 3 , O. Elicin 2 1 Inselspital- Bern University Hospital, Department of Otorhinolaryngology- Head and Neck Surgery, Bern, Switzerland; 2 Inselspital- Bern University Hospital, Department of Radiation Oncology, Bern, Switzerland; 3 Inselspital- Bern University Hospital and Sant'Orsola-Malpighi Hospital- University of Bologna- Italy, Department of Otorhinolaryngology- Head and Neck Surgery and Sensory Organs Department, Bern and Bologna, Switzerland Purpose or Objective The treatment of laryngeal squamous cell carcinoma (SCC) is a challenging since the functional outcome is tightly related to the quality of life of the affected patients. With the emergence of organ sparing treatment options the rate of laryngeal preservation has increased during the past decades. The aim of this study is to describe the long- term morbidity and functional outcomes associated with the different treatment modalities for laryngeal SCC at our tertiary reference center. Material and Methods We reviewed all patients undergoing curatively intended treatment for laryngeal SCC at our tertiary referral center from 1997 to 2014. Results A total of 477 patients were enrolled in the present study. The median follow-up of surviving patients was 51 months. Overall survival at 5 years was 79%. (Chemo)radiotherapy (CRT) with or without concomitant systemic treatment was the dominant (75%) modality, whereas 25% underwent primary surgery. In the latter group, 72% required adjuvant treatment. The 5-year laryngectomy-free survival was 57% vs. 69% with primary surgery vs. primary CRT, respectively (p<0.01). In stage III-IVB, these rates were 26% vs. 47%, respectively (p<0.01). The risk of having a permanent or transient tracheostomy was 53.4% and 29.5% in patients who were primarily treated with surgery and CRT, respectively (p<0.01). Tracheostomy at the time of last of follow-up was 39% after primary surgery and 21% after primary CRT (p<0.01). The risk of requiring a feeding tube (FT) at any time point was 51.7% and 30.4% in primary surgery and primary CRT groups, respectively (p<0.01). Permanent FT was 3.4% after primary surgery, 5% after primary CRT (p=0.45). Primary surgery (HR: 1.67, 95% CI: 1.19-2.32; p<0.01) and stage III-IVB (HR:4.07, 95% CI: 2.97-5.60; p<0.01) remained as adverse factors for laryngectomy-free survival. Conclusion In this study, we report a full conservation of laryngeal function in 75% of the patients undergoing curatively intended treatment for laryngeal SCC of all stages. Advanced tumor stages are related to a poor functional outcome. Preserving the laryngeal function in larynx